Greek environmental health SME specialising in endocrine disruptor testing, urban exposome research, and systems toxicology for H2020 consortia.
ENVE.X is a Greek environmental health SME based in Thessaloniki, operating at the intersection of environmental exposures and human health outcomes. Their work covers two distinct but related domains: computational toxicology and integrated testing strategies for identifying chemical hazards (specifically endocrine disruptors linked to metabolic disorders), and urban environmental health research examining how city environments shape physical and mental wellbeing. They contribute scientific and technical expertise to large European research consortia, applying tools such as systems toxicology, omics, and adverse outcome pathways (AOPs) alongside community-based methods like living labs and citizen science. The company name "ENVE.X" signals their core identity as an environmental science specialist bridging laboratory-scale hazard assessment and population-level environmental health.
In OBERON (2019–2024), they contributed to IATA-based strategies for identifying endocrine disruptors linked to metabolic disorders, using AOPs, omics, and in vitro/in vivo models including zebrafish and human cells.
In URBANOME (2021–2025), they participated in a multi-city urban health observatory studying how environmental stressors, inequality, and urban design affect physical and mental health via exposome approaches.
OBERON relied on computational modelling and molecular mechanism analysis as core methodological tools, indicating ENVE.X has capacity in in silico toxicology workflows.
URBANOME introduced living labs, citizen science, and participatory governance into ENVE.X's portfolio, signalling a capability shift toward community-engaged environmental health research.
Their early H2020 work was firmly rooted in molecular and computational toxicology — identifying chemical hazards at the cellular and systems level, building testing frameworks for endocrine-disrupting compounds, and working with biological models like zebrafish and omics data. By 2021, the focus had broadened considerably toward urban-scale environmental health: exposome, social determinants, participatory governance, and nature-based solutions. Both projects share an underlying thread — environmental stressors and their health consequences — but the methods and scale shifted from laboratory bench to city-wide population studies.
ENVE.X appears to be expanding from molecular environmental toxicology into the broader field of urban environmental health, making them a candidate partner for projects combining chemical exposure science with city-level health equity and citizen engagement.
ENVE.X has participated exclusively as a consortium partner across both projects — they have never held a coordinator role, suggesting they operate as a specialist contributor rather than a project leader. Both projects are large RIA consortia (OBERON and URBANOME span 5-year durations with multi-million Euro budgets), indicating comfort working within complex, multi-partner structures. With 27 unique partners across 11 countries from just two projects, their network is broad relative to their size, suggesting they are brought in specifically for their niche environmental health expertise.
Despite only two projects, ENVE.X has connected with 27 unique consortium partners spanning 11 countries — an unusually wide network for an SME of this size, reflecting the large pan-European consortia typical of RIA health projects. No geographic concentration is discernible from the available data.
ENVE.X occupies a rare niche as a small private company that combines hard-science toxicology (AOPs, omics, IATA) with socio-environmental urban health research — a combination rarely found in a single SME. Based in Thessaloniki, they represent the kind of lean, expert consultancy that large consortia actively seek to satisfy SME participation requirements while delivering genuine scientific depth. For a consortium builder, they offer a credible Greek partner with demonstrable track record in both regulatory toxicology contexts and urban health observatories.
